Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.
Akeso reported overall survival benefit for ivonescimab plus chemotherapy in Phase III lung cancer study. The company enrolled first patient in Phase Ib/II trial of next-generation HER3 ADC AK138D1 for advanced breast cancer. Akeso also received China approval to start Phase II trials for AK139 bispecific antibody.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
A $3.2 million research collaboration is developing a drug that directly breaks down MDM2 in triple-negative breast cancer. Early laboratory models showed tumour shrinkage, and the team is studying dosing, safety and performance.
A preclinical study in Cancer Letters found that pairing targeted treatments with CAR T-cell therapy may help control recurrence in triple-negative breast cancer. In laboratory and mouse models, the approach slowed tumor growth and reduced spread to the lungs and liver.
Zentalis selected a 400 mg once-daily, 5-days-on/2-days-off azenosertib regimen for Cyclin E1-positive platinum-resistant ovarian cancer after a DENALI Phase 2 interim analysis. The regimen is planned for DENALI and ASPENOVA as the company pursues a potential accelerated approval pathway.
A novel therapeutic vaccine using structural nanomedicine principles has shown promising results against HPV-driven cancers in preclinical models. The spherical nucleic acid vaccine design significantly slowed tumor growth and extended survival by generating potent T-cell responses. Unlike preventive HPV vaccines, this approach is designed to treat established cancers caused by the virus.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07610525 |
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07533123 |
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care |
RECRUITING | PHASE3 |
| NCT07528768 |
Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07503808 |
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
RECRUITING | PHASE1 |
| NCT07478705 |
Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging |
NOT_YET_RECRUITING | NA |
| NCT07423117 |
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07357948 |
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy |
NOT_YET_RECRUITING | NA |
| NCT07341867 |
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype |
NOT_YET_RECRUITING | PHASE1 |
| NCT07340541 |
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies |
RECRUITING | PHASE2 |
| NCT07332975 |
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC |
RECRUITING |
